Yves Bikorimana: What Every Lab and Clinician Should Know on Pseudothrombocytopenia
Yves Bikorimana, CEO at MedData-Rwanda and Lab Scientist at The University Teaching Hospital of Kigali-Chuk, shared a post on LinkedIn.
“Pseudothrombocytopenia (PTCP): What Every Lab and Clinician Should Know
Pseudothrombocytopenia is a laboratory artifact where platelet counts appear falsely low on automated analyzers, despite the patient having a normal platelet count in vivo. Importantly, it is not a true clinical thrombocytopenia and does not increase bleeding risk.
Why does it happen?
The most common cause is EDTA-dependent platelet clumping. In some individuals, EDTA (the anticoagulant used in routine CBC tubes) exposes platelet surface antigens, leading to antibody-mediated platelet aggregation. Automated analyzers then misinterpret these clumps as leukocytes or exclude them entirely, resulting in a falsely low platelet count.
Key Laboratory Features
- Low platelet count on automated CBC
- Platelet clumps visible on peripheral blood smear
- Normal platelet count when blood is collected in:
- Sodium citrate
- Heparin
- Magnesium sulfate (rarely used but effective)
Clinical Significance
- Patients are usually asymptomatic
- No bleeding manifestations
- Can be mistaken for serious conditions like:
- Immune thrombocytopenic purpura (ITP)
- Bone marrow disorders
- Drug-induced thrombocytopenia
Why recognition matters
Failure to identify PTCP can lead to:
- Unnecessary platelet transfusions
- Inappropriate treatments (e.g., steroids, IVIG)
- Delays in surgeries or invasive procedures
- Patient anxiety and misdiagnosis
Best Practice Approach
- Always review the peripheral smear when thrombocytopenia is detected
- Repeat platelet count using an alternative anticoagulant
- Correlate laboratory findings with clinical presentation
Take-home message
Pseudothrombocytopenia highlights the importance of laboratory-clinical correlation and the continued value of manual smear examination in modern diagnostics.”
Find the latest updates on Hemostasis Today.
-
Feb 11, 2026, 17:00A Major Step Forward for the Global Bleeding Disorders Community – Haemophilia Foundation Australia
-
Feb 11, 2026, 16:47Pall T. Onundarson and Mandeep Mehra on Diverse Approaches to Anticoagulation in LVAD Patients
-
Feb 11, 2026, 16:37Rahul Gosain: Are Cancer Outcomes Directly Related to Lymphocyte Counts?
-
Feb 11, 2026, 16:35Are DOACs Actually Safer in Advanced Cirrhosis – RPTH Journal
-
Feb 11, 2026, 16:33Reza Shojaei: Transforming Canada’s Plasma System for Greater Resilience and Self-Sufficiency
-
Feb 11, 2026, 16:31Pat Garcia-Gonzalez: A Bold Plan to Double Impact and Reach 100,000 Patients by 2031
-
Feb 11, 2026, 16:20Ney Carter Borges։ Clinical Importance of Coronary Microcirculation in MINOCA and INOCA
-
Feb 11, 2026, 16:18The Hidden Risks of Blood Thinners and the Need for Safer Anticoagulants – National Blood Clot Alliance
-
Feb 11, 2026, 16:13Thomas Reiser: A Great Opportunity to Advance the Field of Thrombosis and Hemostasis